Silverio Ros
Hospital Universitario Virgen de la Arrixaca · 42 works · 403 citations · h-index 11
Top works
- Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
- CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.
- Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD)
- Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
- Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
- SEOM clinical guidelines for anaemia treatment in cancer patients (2020)
- High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1
- Immunoscore: a novel prognostic tool. Association with clinical outcome, response to treatment and survival in several malignancies
- Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer
- “High Tumor Burden” in Metastatic Non-Small Cell Lung Cancer: Defining the Concept
- Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first‐line anti‐programmed death‐1 monotherapy: A real‐world multicentre observational cohort study
- Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients
- Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145).
- SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)
- Prognostic significance of thromboembolic events in chemotherapy-treated germ cell tumors.
- Bone Health in Metastatic Hormone-Sensitive Prostate Cancer: Where We Stand and Where We Can Improve
- Incidence and Survival of IDH-Wildtype Glioblastoma and IDH-Mutant Astrocytoma by Treatment and Sex: A Regional Study in Spain (2011–2021)
- Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer
- Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation.
- Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study